Modular Medical Inc (MODD)

A. Company Overview

Modular Medical Inc. is a pre-revenue medical device company that specializes in the design, development, and commercialization of innovative insulin pumps aimed at improving the management of diabetes. The company's primary focus is to modernize and simplify insulin delivery systems, thereby increasing accessible options for individuals managing diabetes, particularly targeting type 1 and type 2 diabetes markets. Modular Medical aims to broaden insulin pump adoption among people who require daily insulin therapy, moving beyond the limited user base of highly motivated, tech-savvy individuals typically classified as "super users."

The company's flagship product, the MODD1 insulin pump, is an innovative two-part patch pump designed to address the cost and complexity barriers associated with traditional insulin pumps. The MODD1 aims to provide a user-friendly experience through streamlined processes that include everything from patient onboarding and prescription assistance to insurance reimbursement and clinical support. By simplifying these aspects, Modular Medical envisions expanding the wearable insulin delivery device market into a mass market.

B. Market Differentiation

Modular Medical has identified several shortcomings in currently available insulin pumps that hinder widespread adoption among those who necessitate insulin. These include issues such as cumbersome user interfaces, extensive training requirements, high costs, and inadequate insurance coverage. To tackle these challenges, the company has set out to provide an insulin pump that is more intuitive, less time-consuming to operate, and more accessible in terms of affordability and insurance coverage.

Research conducted into the perspectives of potential users—specifically those termed "Almost Pumpers," refers to insulin-requiring individuals who are aware of insulin pumps but remain on multiple daily injection (MDI) therapy due to concerns over current devices—has informed the design of the MODD1. This patient-centric approach, which involves interviews and feedback from over 200 individuals, demonstrates the company's commitment to understanding real-world barriers to insulin pump adoption.

C. Product Overview

The MODD1 insulin pump is poised to be a disruptive force in the diabetes care landscape. Key features include a proprietary design that allows for both basal and bolus insulin delivery, utilizing a high-precision pumping method that improves the consistency and efficiency of insulin administration. With a simplified setup requiring only nine steps compared to the typical 42 steps for most existing pumps, the MODD1 is intentionally designed for ease of use.

Further emphasizing patient convenience, the MODD1 includes features such as a disposable cartridge that users can easily fill with insulin, a low-power Bluetooth and near-field communication (NFC) chip for mobile interaction, and an intuitive button for insulin delivery. By minimizing the complexities previously associated with insulin delivery and eliminating the need for separate controllers, the MODD1 pump aims to enhance user experience and drive better health outcomes.

D. Market Landscape and Opportunity

The global diabetes prevalence is substantial, with approximately 537 million individuals affected, expected to increase to 783 million by 2045. In the United States, about 34 million people live with diabetes, with 1.8 million having type 1 diabetes (T1D) and a significant portion of the 32.2 million individuals with type 2 diabetes (T2D) relying on MDI therapy for management. Despite insulin pumps offering improved control over diabetes management, only about one-third of T1D patients utilize pumps, indicative of a large untapped market segment referred to as "Almost Pumpers."

This segment is characterized by individuals who understand the advantages of insulin pumps but face obstacles such as costs, complexity, and intimidation factors associated with current devices. Modular Medical estimates this market could represent a growth opportunity of approximately $1.9 billion specifically for T1D patients. By capitalizing on the MODD1's ease of use, affordability, and enhanced insurance reimbursement strategies, the company is well-positioned to transition these Almost Pumpers into users of insulin pump technologies.

E. Technological Advantages

Modular Medical’s MODD1 pump incorporates innovative manufacturing methodologies adapted from consumer electronics, which allows for high-volume production and cost-effective manufacturing. The design is tailored for easy assembly, promising lower production costs and a more affordable price point for consumers. The MODD1 system's unique advantages include a light-weight structure, more insulin capacity than competing pumps, and user-friendly operational features that minimize dependency on external devices for management.

The pump's compact size, minimal steps for operation, and ability to reattach after removal addresses commonly reported pain points associated with existing systems, thereby increasing user confidence and satisfaction. By leveraging proprietary fluid movement technology, the MODD1 aims to provide the most even insulin delivery in the industry, closely mimicking the natural function of the pancreas.

F. Clinical Development and Regulatory Pathway

The pathway to commercialization involves navigating extensive regulatory processes, including achieving FDA clearance for medical devices. As of January 2024, Modular Medical submitted a 510(k) premarket notification to the FDA for the MODD1 insulin pump, a process that is crucial for gaining permission to market the device in the United States. The company received initial feedback from the FDA in March 2024 and is actively addressing their comments as it prepares to transition production operations to a contract manufacturing partner, Phillips-Medisize.

G. Marketing and Commercialization Strategy

Modular Medical’s marketing strategy is designed to first establish the MODD1 as the preferred option for new pump patients, especially targeting the Almost Pumper market segment and those motivated by continuous glucose monitoring (CGM) technology. The approach includes collaboration with telehealth providers to enhance the accessibility of diabetes care and facilitate user training through remote support.

A "soft launch" will follow FDA approval, where the company will work with select clinicians to gather feedback and refine the product and support systems before full commercial rollout. This plan aims to ensure that the MODD1 will not only meet regulatory requirements but will also satisfy patient and provider needs effectively.

H. Future Outlook

Looking ahead, Modular Medical is focused on evolving the MODD1 pump to address patient needs and market dynamics continuously. The company intends to monitor and refine the technology further, exploring potential applications beyond diabetes treatment as it aims to solidify its position as a leader in insulin pump therapy. With a strong emphasis on usability, affordability, and practical functionality tailored for both type 1 and type 2 diabetes, Modular Medical is set to create a significant impact in the medical device landscape aimed at diabetes management.